US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.30

+1.091.81%

Post-market: 61.28-0.0200-0.03%19:30 EDT

Volume:40.39K

Turnover:2.46M

Market Cap:296.69M

PE:20.05

High:61.51

Open:60.28

Low:59.85

Close:60.21

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.81

T/O Rate:0.83%

Dividend:1.52

Dividend Rate:2.48%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Top Premarket Gainers

MT Newswires Live

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study

Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

Roivant Sciences Ltd - Phocus Met Its Primary Endpoint

THOMSON REUTERS

Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study

THOMSON REUTERS

Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study

THOMSON REUTERS

Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile

THOMSON REUTERS

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS

Guardant Health initiated with a Buy at Rothschild & Co Redburn

China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily

Medical Device Inspection Campaign Launched by Ningyang County Market Regulators

MedTech Firm Joins Hong Kong Market: Evaluating MEDCAPTAIN's (02041) True Investment Potential

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/PTH/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.3,"timestamp":1791230400000,"preClose":60.2082,"halted":0,"volume":40391,"hourTrading":{"tag":"盘后","latestPrice":61.28,"preClose":61.3,"latestTime":"19:30 EDT","volume":10,"amount":612.9200000000001,"timestamp":1791243002997,"change":-0.02,"changeRate":-0.000326,"amplitude":0.000326},"delay":0,"changeRate":0.01813374257991435,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Post-Mkt","change":1.0918,"latestTime":"10-05 19:30:30 EDT","open":60.28,"high":61.5094,"low":59.85,"amount":2458262.703195,"amplitude":0.027561,"askPrice":61.85,"askSize":4900,"bidPrice":60.76,"bidSize":4900,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791244800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":60.2082,"sharesOutstanding":2480000,"nav":59.60729,"aum":291451253.04,"dividendRate":0.02485,"bidAskSpread":0.001966,"preHourTrading":{"tag":"盘前","latestPrice":60.2082,"preClose":60.2082,"latestTime":"07:36 EDT","volume":16,"amount":963.658208,"timestamp":1791200176330,"change":0,"changeRate":0,"amplitude":0.000362},"postHourTrading":{"tag":"盘后","latestPrice":61.28,"preClose":61.3,"latestTime":"19:30 EDT","volume":10,"amount":612.9200000000001,"timestamp":1791243002997,"change":-0.02,"changeRate":-0.000326,"amplitude":0.000326},"volumeRatio":0.808108,"impliedVol":0.1491,"impliedVolPercentile":0.757},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.808108,"shares":4840000,"dividePrice":1.5233,"high":61.5094,"amplitude":0.027561,"preClose":60.2082,"low":59.85,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.3,"eps":3.057033,"divideRate":0.02485,"volume":40391,"delay":0,"ttmEps":3.057033,"open":60.28,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":61.8701,"twentyDayClose":61.1284,"sixtyDayClose":59.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BME","BBP","AZNH","JDOC","GNOM","MRNY","CNCR","FHLC","PBPH","LFSC","RSPH","WDNA","GDOC","PJP","BIB","CANC","GNMX","GSKH","IBRN","SURI","PSIL","TBXU","CURE","FXH","PINK","SBIO","FTXH","SYNB","LENZ","IBB","PTH","NVIB","APXH","BBH","MEDI","HYLG","HRTS","JHMH","MNTL","GPCR","FBT","MDTX","PBE","IBBQ","PSCH","XPH","IBBJ","LLYX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","GNMX","LU0320765992.SGD","LFSC","GNOM","BK4585","HELX","FFOX","BK4588","LU0889565916.HKD","LU0109394709.USD","EKG","BK4535","BK4196","GDOC","BK4551","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322709","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322709","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322709?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:15","pubTimestamp":1788866115,"startTime":"0","endTime":"0","summary":"CEA Industries  shares were up over 63% in Tuesday's premarket activity following a 6.1% rise in the prior trading session on Thursday.GMEX Robotics  stock was 23% higher, swinging from the 5.5% loss in the earlier sessionRoivant Sciences  shares were up 23% after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.Upstream Bio  stock was 11% higher after the company said it presented phase 2 clinical trial results for its lead severe asthma treatment candidate, verekitug, at the European Respiratory Society Congress in Barcelona.Eightco  shares were up 8% following a 6.8% fall in the prior session.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4200","ROIV","BNC","UPB","BK4136","BK4086","GMEX","BK4139","PTH","ORBS","BK4007","BK4220"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324029","title":"Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324029","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324029?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:51","pubTimestamp":1788864660,"startTime":"0","endTime":"0","summary":"Shares of Roivant Sciences climbed after the company disclosed what it called positive results from a mid-stage trial evaluating its treatment for some instances of pulmonary hypertension, or high blo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665248463","title":"Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665248463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665248463?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:25","pubTimestamp":1788863137,"startTime":"0","endTime":"0","summary":"BUZZ-Roivant Sciences jumps after lung disease drug meets main goal in mid-stage study** Shares of Roivant SciencesROIV.Orise 21.7% to $42.50 premarket** The drug developer's Pulmovant unit says its experimental inhaled therapy, mosliciguat, met the primary goal in a mid-stage study in patients with pulmonary hypertension associated with interstitial lung disease** It is a condition where high blood pressure develops in the lung arteries due to scarring or inflammation in the lungs** The study showed a 56.3% placebo-adjusted reduction in resistance in the lungs' blood vessels at 16 weeks** The drug also met secondary goals: improving six-minute walk distance by 35.2 meters vs placebo; reducing levels of NT-proBNP, a biomarker of cardiac strain, by 53.2% at week 16** Cough, a common side effect associated with inhaled prostacyclin therapies, was reported in 12.1% of patients receiving mosliciguat vs 18.2% on placebo** ROIV says it has already initiated the late-stage study of moslicigua","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321166","title":"Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321166?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862233,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0J3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443549.SGD","EKG","LU0320765992.SGD","LU2236285917.USD","AZN","BK4551","LU0432979614.USD","LU2237443465.HKD","LU2456880835.USD","BK4007","GH","LU0889565916.HKD","LU0708994859.HKD","BK4585","LU0128525929.USD","BK4568","LU1267930573.SGD","LU2237443382.USD","LU0310800379.SGD","LU2237443622.USD","LU1829250122.USD","AZNH","GNMX","HELX","LU0029864427.USD","LU0058720904.USD","LU2237443978.SGD","LABU","FFOX","LU2462157665.USD","BK4588","LU0289739699.SGD","PTH","LU2417539215.USD","IE00B3T34201.USD","GNOM","BK4196","LU2089984988.USD","GDOC","LU2237443895.HKD","LU2468319806.SGD","LFSC","LU0109394709.USD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732139","title":"Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732139","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732139?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:02","pubTimestamp":1788861725,"startTime":"0","endTime":"0","summary":"Roivant says Phase 2 PHocus trial shows mosliciguat cuts pulmonary vascular resistance 56.3% in PH-ILDRoivant reported positive Phase 2 results for inhaled mosliciguat in pulmonary hypertension tied t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLbzhjky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","PTH","BK4551","BK4535","BK4585","GNOM","HELX","LU0320765992.SGD","FFOX","GDOC","BK4588","LU0109394709.USD","EKG","GNMX","BK4196","GH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932902","title":"Roivant Sciences Ltd - Phocus Met Its Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932902?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329027","title":"Roivant Announces Positive Results from Phocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (Ph-Ild) and Unveils Ongoing Phase 3 Phrontier Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329027?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTH","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329008","title":"Roivant Sciences - Mosliciguat Shows Lower Cough Incidence than Placebo in Phocus Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329008?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321399","title":"Roivant Sciences Ltd - Mosliciguat Observed to be Well Tolerated with a Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321399?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665218033","title":"Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2665218033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665218033?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA6HNRNG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532615","title":"Guardant Health initiated with a Buy at Rothschild & Co Redburn","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532615","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532615?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:16","pubTimestamp":1788858969,"startTime":"0","endTime":"0","summary":"Rothschild & Co Redburn initiated coverage of Guardant Health (GH) with a Buy rating and $203 price target The firm says Guardant is the leader in ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-initiated-with-a-buy-at-rothschild-co-redburn-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","HELX","EKG","LU0109394709.USD","BK4551","LU0889565916.HKD","PTH","BK4196","BK4535","BK4588","FFOX","GDOC","GNMX","LU0320765992.SGD","BK4585","GNOM","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106413707","title":"China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily","url":"https://stock-news.laohu8.com/highlight/detail?id=1106413707","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106413707?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:34","pubTimestamp":1788838468,"startTime":"0","endTime":"0","summary":"China Securities has released a research note indicating that the medical device sector maintained its revenue growth trajectory in Q2, with quarterly profit growth turning positive for the first...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0276","PTH","MEDX","HART","MDEV","RSPH","601066","BK1100","LGHT","LNGR","BK1574","AGNG","GDOC","09996","159883","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155170383","title":"Medical Device Inspection Campaign Launched by Ningyang County Market Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=1155170383","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155170383?lang=en_us&edition=fundamental","pubTime":"2026-09-07 12:41","pubTimestamp":1788756073,"startTime":"0","endTime":"0","summary":"On September 7, enforcement officers from the Market Supervision Administration of Ningyang County, Shandong Province, visited retail pharmacies within their jurisdiction to conduct a targeted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","GDOC","IEIH","MEDX","HART","AGNG","LGHT","MDEV","BK1583","PTH","09996","BK1100","RSPH","159883","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191894169","title":"MedTech Firm Joins Hong Kong Market: Evaluating MEDCAPTAIN's (02041) True Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1191894169","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191894169?lang=en_us&edition=fundamental","pubTime":"2026-09-07 12:18","pubTimestamp":1788754720,"startTime":"0","endTime":"0","summary":"As a wave of interim earnings reports floods in from medical device companies, the sector's recovery trajectory has become increasingly clear, with a definitive upward inflection point now visible in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","PTH","VXUS","BK1574","BK1100","KCAI","09996","RSPH","159883","02041","IEIH","GDOC","MEDX","HART","BK4588","BK4585","BK1583","LNGR","LGHT","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665692103","title":"Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665692103","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665692103?lang=en_us&edition=fundamental","pubTime":"2026-09-06 13:00","pubTimestamp":1788670818,"startTime":"0","endTime":"0","summary":"Roivant to present Phase 2 PHocus mosliciguat topline data in PH-ILD at ERS Congress Sept. 8, 2026Roivant flagged upcoming topline results from its Phase 2 PHocus study of mosliciguat in pulmonary hyp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nNDL92hcqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121796426","title":"Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796426?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:10","pubTimestamp":1788588618,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held September 4-6 in Chengdu, Sichuan, under the theme \"Enterprise Innovation and Cycle Crossing,\" Formatia Founder and CEO Peng Lei offered a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","AGNG","BK1574","PTH","BK1100","159883","IBRN","LGHT","MDEV","09996","RSPH","BK1583","LNGR","GDOC","MEDX","IEIH","HART"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}